Strong point:
Weaker points:
The headline, “Experimental treatment may help food allergies,” promises more than what the story delivers.
There wasn’t any estimate given of the cost of oral immunotherapy, nor of the drug mentioned at the end of the article that is being studied for use against food allergies.
The story reported benefits in this way:
The results suggested that children who went through a year of sublingual therapy followed by one to two years of oral immunotherapy were less likely to have significant allergic reactions when undergoing the oral immunotherapy. Still, it did not eliminate all symptoms.
Why not quantify/specify what terms like these really mean:
The story didn’t quantify/explain the extent of “significant reactions during the treatments that make the therapy unfeasible” in the new sublingual approach.
There were appropriate caveats about the limitations of the research:
One thing that could have been improved: The story mentioned that the study was “published in the Journal of Allergy and Clinical Immunology” but didn’t link to it as we do here. Basing the story on the talk at the 2012 Annual Meeting of the American Academy of Allergy, Asthma & Immunology and not linking to the journal article might mislead people if they take that to mean it hasn’t undergone the same rigorous peer review as a journal article.
There wasn’t any independent voice in the story.
The story at least ended with mention of one other approach being studied:
Researchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.
As noted, the story made it clear that this is preliminary research and that the approach “may one day” be available.
Then the story quoted the researcher estimating that “the treatment could be brought to the public within six to eight years.”
This is not entirely accurate, as oral immunotherapy for food allergies (including milk allergy) is currently being administered clinically by a handful of physicians. The concept behind the treatment (basically, exposing patients to food proteins) is not FDA regulated, and so there is theoretically no barrier to physicians offering this type of therapy to their patients. Citing the potential for adverse reactions and other concerns, however, most experts say that it is much too soon to use oral immunotherapy outside of a research setting. And so the story’s bottom line message about availability is correct for the vast majority of patients. Still, the estimate of availability “within 6 to 8 years” may cause confusion to parents who have heard, via allergy blogs or other media sources, that it is already available.
The story noted other immunotherapy research that’s been done, but stated “This is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy.”
It does not appear that the story relied solely on a news release.
Systematic, Criteria-Driven
Like Michael Corleone of science reporting that @garyschwitzer is (he tries to get out, bullshit disguised as #science #journalism keeps pulling him back in!), he drops this on @nytimes idiocy 🙄 in reporting T1 diabetes "cure"
HT @HealthNewsRevu
https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like